New dosing schedule aims to make blood cancer drug safer
NCT ID NCT06697184
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 26 times
Summary
This study tests different dosing schedules for the drug sonrotoclax in 56 adults with chronic lymphocytic leukemia (CLL). The goal is to find a safer way to start treatment and reduce the risk of tumor lysis syndrome, a serious side effect. Participants receive sonrotoclax in gradually increasing doses while doctors monitor their safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, NSW 2148, Australia
-
Cabrini Hospital Malvern
Malvern East, Victoria, VIC 3144, Australia
-
Chu Dijon
Dijon, 21000, France
-
Chu Montpellier Hopital Saint Eloi
Montpellier, 34090, France
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215-5418, United States
-
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, 46804, United States
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109-4433, United States
-
Genesiscare St Andrews
Adelaide, South Australia, SA 5000, Australia
-
Iuct Oncopole
Toulouse, 31100, France
-
Linear Clinical Research
Nedlands, Western Australia, WA 6009, Australia
-
Moffitt Cancer Center
Tampa, Florida, 33612-9496, United States
-
Queen Elizabeth Hospital
Birmingham, B15 2TH, United Kingdom
-
Rockingham Hospital
Cooloongup, Western Australia, WA 6168, Australia
-
St Jamess University Hospital
Leeds, LS9 7TF, United Kingdom
-
The Alfred Hospital
Melbourne, Victoria, VIC 3004, Australia
-
The University of Kansas Cancer Center
Westwood, Kansas, 66205-2003, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110-1010, United States
Conditions
Explore the condition pages connected to this study.